JP7572668B2 - 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体 - Google Patents

歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体 Download PDF

Info

Publication number
JP7572668B2
JP7572668B2 JP2020119469A JP2020119469A JP7572668B2 JP 7572668 B2 JP7572668 B2 JP 7572668B2 JP 2020119469 A JP2020119469 A JP 2020119469A JP 2020119469 A JP2020119469 A JP 2020119469A JP 7572668 B2 JP7572668 B2 JP 7572668B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
usag
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020119469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021176829A (ja
JP2021176829A5 (https=
Inventor
克 ▲高▼橋
学 菅井
義人 時田
淳一 ▲高▼木
恵美子 三原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aichi Prefecture
University of Fukui NUC
Kyoto University NUC
University of Osaka NUC
Original Assignee
Osaka University NUC
Aichi Prefecture
University of Fukui NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Aichi Prefecture, University of Fukui NUC, Kyoto University NUC filed Critical Osaka University NUC
Publication of JP2021176829A publication Critical patent/JP2021176829A/ja
Publication of JP2021176829A5 publication Critical patent/JP2021176829A5/ja
Priority to JP2024173323A priority Critical patent/JP2025004094A/ja
Application granted granted Critical
Publication of JP7572668B2 publication Critical patent/JP7572668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
JP2020119469A 2019-07-12 2020-07-10 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体 Active JP7572668B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024173323A JP2025004094A (ja) 2019-07-12 2024-10-02 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2019130153 2019-07-12
JP2019130153 2019-07-12
JP2020080723 2020-04-30
JP2020080723 2020-04-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024173323A Division JP2025004094A (ja) 2019-07-12 2024-10-02 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Publications (3)

Publication Number Publication Date
JP2021176829A JP2021176829A (ja) 2021-11-11
JP2021176829A5 JP2021176829A5 (https=) 2023-06-14
JP7572668B2 true JP7572668B2 (ja) 2024-10-24

Family

ID=74209883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020119469A Active JP7572668B2 (ja) 2019-07-12 2020-07-10 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
JP2024173323A Pending JP2025004094A (ja) 2019-07-12 2024-10-02 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024173323A Pending JP2025004094A (ja) 2019-07-12 2024-10-02 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Country Status (6)

Country Link
US (1) US20220259298A1 (https=)
EP (1) EP4000633A4 (https=)
JP (2) JP7572668B2 (https=)
KR (1) KR20220034176A (https=)
CN (2) CN114364694B (https=)
WO (1) WO2021010346A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4115889A4 (en) * 2020-02-21 2024-10-02 Kyoto University Medicine containing usag-1-targeting rna molecule for tooth regeneration therapy
EP4474394A4 (en) * 2022-02-03 2026-04-15 Univ Kyoto Neutralizing antibody targeting a molecule called USAG-1 for treating tooth regeneration
CN116425870A (zh) * 2023-05-24 2023-07-14 陕西师范大学 一种抗新型冠状病毒n蛋白单克隆抗体31a8及其产品和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502470A (ja) 2007-10-12 2011-01-27 ノバルティス アーゲー スクレロスチンに対する抗体の使用のための組成物および方法
JP2011504501A (ja) 2007-11-21 2011-02-10 アムジエン・インコーポレーテツド Ｗｉｓｅ結合抗体及びエピトープ
JP2012530502A (ja) 2009-06-26 2012-12-06 ジーイー・ヘルスケア・ユーケイ・リミテッド 化学物質の毒性を予測する方法
US20130195856A1 (en) 2006-12-29 2013-08-01 Ossifi Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000405A1 (en) * 1997-06-30 1999-01-07 Genetics Institute, Inc. Secreted proteins
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
CN1618807A (zh) * 2003-11-21 2005-05-25 上海人类基因组研究中心 分泌蛋白及其编码序列和用途
CN1842540B (zh) * 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
WO2011075636A2 (en) * 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
KR102155531B1 (ko) * 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
WO2015120138A2 (en) * 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
KR102876923B1 (ko) * 2015-10-23 2025-10-28 화이자 인코포레이티드 항-il-2 항체 및 조성물 및 이의 용도
KR20190044070A (ko) * 2016-08-03 2019-04-29 넥스트큐어 인코포레이티드 Lair 신호 변환을 조정하기 위한 조성물 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195856A1 (en) 2006-12-29 2013-08-01 Ossifi Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
JP2011502470A (ja) 2007-10-12 2011-01-27 ノバルティス アーゲー スクレロスチンに対する抗体の使用のための組成物および方法
JP2011504501A (ja) 2007-11-21 2011-02-10 アムジエン・インコーポレーテツド Ｗｉｓｅ結合抗体及びエピトープ
JP2012530502A (ja) 2009-06-26 2012-12-06 ジーイー・ヘルスケア・ユーケイ・リミテッド 化学物質の毒性を予測する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABITBOL, Marc Mordekhai et al.，"Sostdc1, a secreted dual BMP and WNT antagonist, is differentially expressed in RCS rdy+ and rdy- r，ARVO Annual Meeting Abstract，2017年，Vol.58, No.610
CHEN, Xiaoyan et al.，"Mesenchymal Wnt/beta-catenin signaling induces Wnt and BMP antagonists in dental epithelium"，Organogenesis，2019年，Vol.15，pp.55-67
CHO, Sung-Won et al.，"Interactions between Shh, Sostdc1 and Wnt signaling and a new feedback loop for spatial patterning，Development，2011年，Vol.138，pp.1807-1816

Also Published As

Publication number Publication date
CN114364694B (zh) 2024-05-10
CN114364694A (zh) 2022-04-15
EP4000633A4 (en) 2024-02-21
EP4000633A1 (en) 2022-05-25
JP2025004094A (ja) 2025-01-14
WO2021010346A1 (ja) 2021-01-21
US20220259298A1 (en) 2022-08-18
CN118307669A (zh) 2024-07-09
KR20220034176A (ko) 2022-03-17
JP2021176829A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
JP7044399B2 (ja) タウ免疫療法
CA2447139C (en) Specific binding proteins and uses thereof
JP2025004094A (ja) 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
CN109415432B (zh) Tau免疫疗法
AU2018291081B2 (en) Use of anti-FAM19A5 antibodies for treating cancers
TW201002344A (en) Monoclonal antibodies against the RGM a protein and uses thereof
PT2576618T (pt) Anticorpos contra gdf8 humano
CN1344275A (zh) 用淀粉样蛋白抗体除去淀粉样蛋白的方法
US9908933B2 (en) Antibody therapy for amyloid beta disease
JP2014511174A (ja) Ａｐｏｅ免疫療法
CN109475625A (zh) 用于治疗脊髓性肌肉萎缩症的组合物和方法
KR20230026489A (ko) 소르틸린을 인지하는 항체
TW202116813A (zh) 用於聚合抗體受體靶向之材料及方法
TW202342516A (zh) 識別分選蛋白的抗體
EP4474394A1 (en) Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment
HK40107636A (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
JPH11180895A (ja) 血管新生阻害剤
HK40073445B (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
HK40073445A (en) Neutralizing antibody for tooth regeneration treatment targeting usag-1 molecule
HK40114319A (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
RU2778572C1 (ru) Фармацевтическая композиция на основе антител к cd40 и ее применение
JP2018508193A (ja) メディンを認識する抗体
HK40116870A (zh) 识别sortilin的抗体
CN114591428A (zh) 抗Dsg1抗体及其应用
HK40022776B (zh) 仅有重链的抗bcma抗体

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241002

R150 Certificate of patent or registration of utility model

Ref document number: 7572668

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150